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CC BY-NC-ND license (http://creativeAbstract Critical-sized craniofacial defect repair represents a significant challenge to recon-
structive surgeons. Many strategies have been employed in an effort to achieve both a func-
tionally and cosmetically acceptable outcome. Bone morphogenetic proteins (BMPs) provide
a robust osteoinductive cue to stimulate bony growth and remodeling. Previous studies have
suggested that the BMP-9 isoform is particularly effective in promoting osteogenic differenti-
ation of mesenchymal progenitor cells. The aim of this study is to characterize the osteogenic
capacity of BMP-9 on calvarial mesenchymal progenitor cell differentiation. Reversibly immor-
talized murine calvarial progenitor cells (iCALs) were infected with adenoviral vectors encod-
ing BMP-9 or GFP and assessed for early and late stages of osteogenic differentiation in vitro
and for osteogenic differentiation via in vivo stem cell implantation studies. Significant eleva-
tions in alkaline phosphatase (ALP) activity, osteocalcin (OCN) mRNA transcription, osteopon-
tin (OPN) protein expression, and matrix mineralization were detected in BMP-treated cells
compared to control. Specifically, ALP activity was elevated on days 3, 7, 9, 11, and 13
post-infection and OCN mRNA expression was elevated on days 8, 10, and 14 in treated cells.
Additionally, treatment groups demonstrated increased OPN protein expression on day 10 and
matrix mineralization on day 14 post-infection relative to control groups. BMP-9 alsostic Surgery Research Council, Hamburg, Germany, August, 2011.
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Osteogenic capacity of BMP-9 269facilitated the formation of new bone in vivo as detailed by gross, microcomputed tomogra-
phy, and histological analyses. Therefore, we concluded that BMP-9 significantly stimulates
osteogenic differentiation in iCALs, and should be considered an effective agent for calvarial
tissue regeneration.
Copyright ª 2015, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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The repair of large, complex craniofacial defects often
poses a challenge to reconstructive surgeons. The primary
goals of an adequate reconstruction include the restoration
of form and function. A return to “normal” or pre-morbid
facial aesthetics is critical in defect repair. In the case of
pediatric patients, an understanding of craniofacial growth
and how the choice of and approach to surgery may impact
it must also be considered. Indications for craniofacial
defect repair are most often related to tumor, trauma, or
congenital disease. For the majority of patients, the
preferred method of reconstruction is to “replace like with
like”. For example, cranioplasty is ideally performed using
the surrounding cranium.1 Secondarily, iliac crest, rib and
scapula are reliable options.2e4 The major limitation,
however, directly relates to the finite supply of autologous
bone. Further complicating outcome is potential donor site
morbidity due to infection, pain, nerve injury, and blood
loss.5
In addition to the physical constraint of bone available
for harvest, reconstructions may fail because transplanted
bone is prone to resorption and reduced biomechanical
strength.6 These challenges inherent to autologous tissue-
based reconstruction have encouraged both surgeons and
basic scientists to seek alternative methods to facilitate
bone growth and healing.7,8 Adjunct strategies are
numerous9 and examples include the placement of bio-
materials within the defect to hasten ossification10,11;
administration of osteoinductive growth factors to augment
the body’s own production of new bone12; and the isola-
tion, expansion, and subsequent stimulation of host
osteoprogenitor cells.13,14 These strategies, however, often
fall short of the desired goals.15,16
One promising approach lies in the application of bone
morphogenetic proteins (BMPs) to critical-sized bone de-
fects (i.e., defects that are unable to heal spontaneously).
BMPs are naturally occurring cytokines that regulate several
integral functions at the molecular level including osteo-
genic differentiation, bone development, and fracture
repair.12 Recombinant human forms (rhBMP) of BMP-2 and
BMP-7 are currently offered for abnormalities of bony
healing both within and outside of the craniofacial skel-
eton.17,18 A growing body of literature has demonstrated
the osteoinductive effects of BMPs on craniofacial bone
growth as well.19,20 Our laboratory recently demonstrated
that mesenchymal progenitor cells derived from juvenile
murine calvarium preferentially differentiate toward bone
in the presence of BMP-2.18 Ironically, despite a relative
paucity of research examining the effects of BMP-9 on boneformation, particularly with respect to the craniofacial
skeleton, comprehensive analyses of 14 human BMP iso-
forms demonstrated that BMP-9 displays the greatest de-
gree of osteogenic potential.21e23 To elucidate the
potential role of BMP-9 in craniofacial defect repair, the
current study characterizes and quantifies the osteogenic
effects of BMP-9 on calvarial mesenchymal progenitor cells.
This study is the first to our knowledge to examine BMP-9 in
the context of cranial bone engineering.
Materials & methods
Isolation and culture of calvarial mesenchymal
progenitor cells
Calvariae were isolated from three-week old male CD-1
mice (Charles River, Wilmington, MA, USA) as described
previously.18 This investigation was approved by the Insti-
tutional Animal Care and Use Committee of the University
of Chicago (Chicago, IL), and animal maintenance and
experimental treatments were conducted in accordance
with the ethical guidelines set forth by this committee. All
procedures were conducted under sterile conditions.
Mice were sacrificed and calvariae were harvested by
creating a mid-sagittal incision. The periosteum was incised
to expose the calvarium on both sides of the midline. Soft
tissue, dura and remaining periosteum were removed. The
isolated calvaria were treated as previously described.18
Cultures were incubated at 37 C, 95% humidified air, and
5% CO2. After approximately 7 days, cells grew to 80%
confluency (% of cells covering the plate) at which point
they were passaged by enzymatic digestion (0.1% Trypsin,
SigmaeAldrich) to 25 cm2 flasks containing 8 mL DMEM with
10% FBS and 1% penicillin/streptomycin for
experimentation.
Reversible immortalization of primary calvarial
cells
To allow for ease of culturing and preservation of cellular
growth, harvested primary calvarial cells were allowed to
grow in culture for 5 weeks and then underwent immor-
talization using a retroviral-mediated vector as previously
described.18,24 Previous work has shown that the immor-
talization process does not significantly alter cell
morphology and that immortalized cells maintain expres-
sion of surface antigens typically expressed by primary
mesenchymal progenitor cells.18 An added feature of this
transduction technology is the ability to revert the
270 C.M. Teven et al.immortalized target back to a primary cell. All in vitro and
in vivo experimentation was performed using immortalized
calvarial cells (iCALs).
Recombinant adenoviral vectors
Recombinant adenoviruses were generated using AdEasy
technology as previously described.22,25e27 The coding re-
gion of human BMP-9 was PCR amplified and cloned into an
adenoviral shuttle vector and subsequently used to generate
recombinant adenoviruses in HEK293 cells (American Type
Culture Collection, Manassas, Virginia). The resulting ade-
noviruses were designated as AdBMP-9. Green fluorescence
protein (GFP), which served as a marker of infection effi-
ciency, was included in the vector. Analogous adenovirus
expressing only monomeric GFP (AdGFP) was used as a
control. Serial titrations of the adenoviruses were per-
formed to determine the viral dosage that optimized viral
infection and cell viability. All samples were exposed to virus
for up to 24 h prior to changing the medium. Immortalized
cells were transduced with AdBMP-9 or AdGFP.
Alkaline phosphatase (ALP) activity
Cells were seeded into 24-well cell culture plates at a
density of 2  104 cells/cm2 and cultured in DMEM con-
taining 10% FBS and 1% penicillin/streptomycin for 3, 7, 9,
11, and 13 days with AdBMP-9 and AdGFP (control). ALP
activity was assessed quantitatively with a modified assay
using the Great Escape SEAP Chemiluminescence assay kit
(BD Clontech, Mountain View, CA) and qualitatively with
histochemical staining assay (using a mixture of 0.1 mg/
mL napthol AS-MX phosphate and 0.6 mg/mL Fast Blue BB
salt) as described.21,28 Each assay condition was per-
formed in triplicate and the results were repeated in at
least three independent experiments. ALP activity was
normalized by total cellular protein concentrations among
the samples.
Alizarin red S staining
Immortalized calvarial cells were plated into 12-well tissue
culture plates at a density of 2  104 cells/cm2 and cultured
for 14 days with DMEM containing ascorbic acid (50 mg/mL)
and b-glycerophosphate (10 mM) with AdBMP-9 and AdGFP
treatments. Fresh culture medium was added to each well
every 4 days and nodule formation was routinely checked
by phase contrast microscopy. The presence of mineralized
nodules was determined by Alizarin red staining as
described.21 Briefly, cells were washed with 1% PBS and
fixed with 2.5% glutaraldehyde at room temperature for
10 min. Fixed cells were incubated with 0.4% alizarin red S
(SigmaeAldrich) for 15 min followed by washing with
distilled water. Stained cells were further incubated with
PBS for 5 min. Mineralization was assessed via bright field
microscopy.
RNA isolation and semi-quantitative RT-PCR
Total RNA was isolated using TRIZOL Reagents (Invitrogen,
Carlsbad, CA, USA) and cDNA was generated utilizingreverse transcription with random hexamers and Super-
script II RT (Invitrogen). First strand cDNA products were
further diluted 5- to 10-fold and used as PCR templates.
Semi-quantitative RT-PCR was carried out using qPCR
primers (w18 bps) designed by using primer sets for
osteocalcin (OCN) and GAPDH. GAPDH was used as a control
(approximately 150e180 bps). Primers used were as fol-
lows: OCN:sense, 50-CCAAGCAGGAGGGCAATA-30; antisense,
50-TCGTCACAAGCAGGGTCA-30; GAPDH:sense, 50- ACCCAGA
AGACTGTGGATGG-30; antisense, 50-CACATTGGGGGTAGGAA
CAC-30. PCR amplification was carried out with the
following program: denature at 92 C for 20 s, annealing at
55 C, 17 cycles for GAPDH and 22 cycles for OCN. The PCR
products were separated via a 1% agarose gel with 3 mL of
ethidium bromide (10 mg/mL solution) for 15 min at room
temperature at 80 V. Resulting bands were analyzed in a
Kodak image station 440-CF using Kodak 1D 3.6 software.Osteopontin immunohistochemical staining
To confirm the presence of osteopontin (OPN) upregulation
in AdBMP-9-treated iCALs, immunohistochemical (IHC)
staining on post-infection day 10 was performed as
described previously.18 Specifically, rabbit anti-OPN poly-
clonal antibody (1:100; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) was used.Stem cell implantation assay
iCALs were infected with adenovirus encoding BMP-9 or GFP
as indicated. At 16 h post-infection, cells were harvested,
resuspended in PBS and injected (5  106 cells/injection)
into the flanks (subcutaneous) or quadriceps (intramus-
cular) of athymic (nu/nu) mice (4e6 week-old males, Har-
lan Sprague-Dawley). At 5 weeks post-implantation, the
mice were euthanized and the implantation sites were
harvested and analyzed via microcomputed tomography
(microCT) and histochemical staining.microCT analysis
All retrieved specimens were fixed and imaged using
the microCT component of a GE triumph (GE Healthcare)
trimodality preclinical imaging systems as described.28
All image data analyses were performed using Amira
5.3 (Visage Imaging, Inc.) and three-dimensional (3D)
volumetric data were obtained as previously
described.29e33Histological evaluation
Retrieved tissues were fixed in 10% formalin (decalcified, if
necessary) and embedded in paraffin. Serial sections of the
embedded specimens were stained with hematoxylin and
eosin (H&E). Paraffin-embedded sections were deparaffi-
nized and then rehydrated in a graduated fashion. The
deparaffinized samples were subjected to antigen retrieval
and fixation. The sections were stained with H&E and
Masson’s trichrome as previously described.21,22,26,28,34
Fig. 1 Detection of early markers of osteogenic differen-
tiation. (A) Fluorescent microscopy imaging of green fluores-
cent protein (GFP) expression at 24 h post-adenoviral infection
of calvarial cells in GFP (control) and BMP-9 groups. (B) Alka-
line phosphatase activity is a well-established marker of early
osteogenic differentiation. Average relative alkaline phospha-
tase activity in calvarial cells on days 3, 7, 9, 11, and 13 post-
adenoviral infection with BMP-9 (blue bars) or GFP (red bars) is
shown. Experiments were performed in triplicate. Error bars
represent standard error.*P < 0.05, **P < 0.01.
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Statistical analysis was performed using SPSS software (IBM,
Chicago, IL, USA). All values are reported as mean with
associated standard error bars. Differences between two
groups were compared using a student’s unpaired t-test.
P < 0.05 was considered statistically significant.
Results
Expression of adenoviral DNA
All adenovirally treated cells showed approximately equal
GFP expression at 24 h post-infection, which verifies uptake
of the DNA of interest via the adenoviral vectors (Fig. 1A).
Control group cells that were not treated with adenovirus
did not express GFP (data not shown).
Alkaline phosphatase (ALP) activity
ALP activity in cells transduced with AdBMP-9 and AdGFP
was measured for up to 13 days in culture (Fig. 1B). On day
3 post-infection, AdBMP-9-treated cells demonstrated
significantly higher ALP activity compared to cells treated
with AdGFP. Similarly, from post-infection day 7 through
post-infection day 13, ALP activity was significantly
elevated in cells treated with AdBMP-9 compared to control
cells.
Effect of AdBMP-9 on expression of secreted
extracellular proteins
To confirm that the harvested and infected iCALs upregul-
tated osteogenic genes and produced proteins relevant to
extracellular matrix formation upon AdBMP-9 stimulation,
the mRNA level of the late osteogenic marker gene osteo-
calcin (OCN) was assessed via RT-PCR. Levels of OCN mRNA
were elevated in the AdBMP groups on days 8, 10, and 14
(Fig. 2A). Additionally, osteopontin (OPN) protein expres-
sion was elevated in the AdBMP groups by day 10 (Fig. 2B).
Mineralized nodule formation
To examine the mineralization capacity of the iCALs in the
presence of BMP and GFP, mineral nodule formation was
assessed on day 14 of culture in cells grown in the presence
of AdBMP-9 or AdGFP via alizarin red S staining (Fig. 2C).
Alizarin red S staining intensity of samples was higher by
day 14 in AdBMP-treated groups compared to AdGFP
controls.
Transduction of iCALs with AdBMP-9 enhances bone
formation in vivo
Using the well-established stem cell implantation assay
(Fig. 3A),18 we tested the hypothesis that BMP-9 would
induce a significant osseous response in vivo. GFP-treated
cells produced miniscule bone nodule formation at im-
plantation sites. In contrast, BMP-9-treated cells produced
bone nodules that were significantly larger (Fig. 3B and C).Ectopic bone derived from BMP-9 treated cells had a
similar appearance and quality on microCT analysis to
native bone (Fig. 3D). Histological survey of these masses
revealed more mature bone and thicker trabeculae in BMP-
9-treated cells compared to cells treated with GFP
(Fig. 4A). Additionally, Mason’s trichrome staining demon-
strated matrix mineralization in the osseous nodules
formed by BMP-9-stimulated cells (Fig. 4B).
Discussion
The search for methods to facilitate bony healing within the
craniofacial skeleton has led to the development of many
novel therapies. Synthetic materials including ceramics,
titanium, porous polyethylene, and demineralized bone
matrix have demonstrated efficacy but are associated with
infection, the inability to expand with the growing
Fig. 2 Detection of late markers of osteogenic differenti-
ation. (A) mRNA expression levels of osteocalcin were
measured in calvarial cells on days 8, 10, and 14 post-
adenoviral infection with BMP-9 or GFP. Internal control with
GAPDH is also shown. (B) Immunohistochemical staining for
osteopontin expression in AdBMP-9 and negative control (NC)
groups at 10 days post infection. (C) Matrix mineralization
(Alizarin red S staining) on post-infection day 14 in cells treated
with AdGFP and AdBMP-9.
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composite defects that are deficient in skin, bone, and/or
dura, a more complex reconstructive approach in the form
of chimeric free flaps may be required.35 More recently, the
concept of tissue engineering has become a promising
strategy for defect repair and/or reconstruction. Tissue
engineering encompasses a broad array of therapies that
include cell-based, growth factor-based, and/or scaffold-
based approaches. The current study investigates the
viability of cell- and growth factor-based strategies for
bone formation.
The delivery of signaling molecules (mitogens, morpho-
gens, and growth factors) to the site of intended repair
describes growth factor-mediated tissue regeneration.36
Many authors have studied the use of BMPs for growth
factor-based craniofacial repair, predominantly focusing on
BMP-2 and BMP-7.12,37 Preliminary work from our laboratory
demonstrated that direct transfer of AdBMP-2 into murine
cranial defects results in improved but incomplete healing
compared to AdGFP controls.38 More recently, AdBMP-2
infection of calvarial-derived osteoprogenitor cells
revealed successful formation of bone in both in vitro and
in vivo.18 Recombinant forms of BMP (rhBMP-2 and rhBMP-7)
have even been used in off-label fashion for particularlycomplex reconstructive challenges of the human craniofa-
cial skeleton with limited success.39,40
Despite abundant research of their osteoinductive
properties and FDA-approval for clinical use, neither BMP-2
nor -7 appears to be the most osteogenic of the BMP sub-
types. Several experiments from our laboratory have
elucidated BMP-9 as a potent inducer of osteogenic differ-
entiation of mesenchymal stem cells (MSCs), demonstrating
greater osteogenicity than both BMP-2 and -7.41 However,
BMP-9 has been one of the least studied isoforms and has
never been examined in the context of cranial defect
repair. Therefore, we analyzed the osteogenic effects of
BMP-9 on calvarial-derived osteoprogenitor cells. ALP ac-
tivity was measured to assess early osteogenic differenti-
ation.42 Compared to control cells, by day 3 post-infection
BMP-9-treated cells demonstrated a significant elevation in
ALP activity. This pattern persisted at all time points, sug-
gesting that BMP-9 stimulates a more pronounced early
osteogenic response than control.
We also determined the osteogenic effect of BMP-9 using
established markers of late osteogenic differentiation.43
Upregulation of OCN mRNA was observed in AdBMP-
treated groups compared to control cells. Similarly,
expression of OPN protein was elevated in treatment groups
compared to control on day 10. This evidence further sup-
ports that BMP-9 is capable of inducing osteogenic differ-
entiation in vitro. Future experiments are needed to
characterize upregulation of other proteins requisite for
BMP signaling (e.g., Runx2 and osterix) in the presence of
AdBMP-9 stimulation.
To assess the final stages of osteogenesis, alizarin red S
staining was used to detect formation of calcium nodules.44
By day 14, treatment cells demonstrated positive staining,
indicating that cells were undergoing the terminal steps of
osteogenic differentiation. Taken together, these results
indicate that BMP-9 stimulation of calvarial mesenchymal
progenitor cells results in significantly greater in vitro bone
production than control.
In contrast to a growth factor-based approach to tissue
engineering, cell-based strategies generally rely on the
direct injection of cells into the site of interest. Cells may
serve as biologic agents to stimulate tissue repair, as bio-
logical vehicles for gene delivery, or a combination
thereof.45,46 In the current study, iCALs provided a vehicle
to deliver BMP to our animal model as well as a rich source
of osteoprogenitor cells capable of forming new bone. Prior
in vivo examination of iCAL behavior has demonstrated its
ability to undergo osteogenic differentiation leading to
bone formation upon BMP-2 stimulation.18 The present
study similarly demonstrated that BMP-9 infection of iCALs
led to greater in vivo bone formation compared to GFP.
These results suggest that BMP-9 is capable of stimulating
bone formation of mesenchymal progenitor cells both
in vitro and in vivo to a degree significantly greater than
control.
At present, there is very limited research examining the
effects of BMP-9 on the craniofacial skeleton. Using direct
adenoviral-mediated BMP therapy, Alden and colleagues
found that mandibular defects treated with AdBMP-9 dis-
played enhanced bony healing compared to controls.47
Here, we reveal that BMP-9 can effectively induce osteo-
genic differentiation of mesenchymal progenitor cells
Fig. 3 Stem cell implantation assay to assess in vivo effects of AdBMP-9 infection. (A) Schematic diagram of experimentation.
(B) Digital photography of representative mice after sacrifice. (C) Representative gross specimens after retrieval. (D) Using microCT
imaging analysis, ectopic osseous nodules (denoted by arrow) derived from BMP-9-treated cells that were injected into mice are
similar in character and appearance to native bone harvested after sacrifice of animals.
Osteogenic capacity of BMP-9 273derived from the calvarium. Future studies should address
whether the combined cell- and growth factor-based
approach to bone engineering used in the current study is
sufficient to heal critical-sized osseous defects. In addition,Fig. 4 iCALs treated with BMP-9 form more mature ectopic bon
and eosin staining of 0.1 mm cross sections of harvested specimen
fibrous cell reaction present in the control group (GFP). Top panel,
trichrome staining of 0.1 mm cross sections of harvested specimen
from iCALs treated with BMP-9. From top to bottom, low to high pin an effort to increase the clinical applicability of our re-
sults, it would be beneficial to test the osteogenic effect of
BMP-9 on mesenchymal progenitor cells isolated from the
human craniofacial skeleton.e than iCALs treated with GFP. (A) Representative hematoxylin
s reveal dense trabecular bone in experimental groups versus
lower power; bottom panel, higher power. (B) Representative
s reveal matrix mineralization in the osseous nodules produced
ower.
274 C.M. Teven et al.Conclusions
We have demonstrated for the first time that BMP-9
effectively stimulates osteogenic differentiation and sub-
sequent bone formation of mesenchymal progenitor cells
isolated from murine calvariae. Further research detailing
the effects and therapeutic application of BMP-9 on human
calvarial mesenchymal progenitor cells should be
performed.
Conflicts of interest
All authors have none to declare.
Financial disclosures
The authors have received no financial support from and
have no interest in any commercial source that is related
directly or indirectly to the scientific work presented in this
article.
Acknowledgments
This work was funded by the Chicago Biomedical Con-
sortium with support from the Searle Funds at The Chicago
Community Trust. The reported work was also supported in
part by an NIH/NIDCK K08 Career Development Award
(#1K08DE020140-01; RRR). This work was also supported in
part by The University of Chicago Core Facility Subsidy
grant from the National Center for Advancing Translational
Sciences (NCATS) of the National Institutes of Health
through Grant UL1 TR000430 (RRR).
References
1. Agrawal A, Garg LN. Split calvarial bone graft for the recon-
struction of skull defects. J Surg Tech Case Rep. 2011;3:13e16.
2. Elsalanty ME, Genecov DG. Bone grafts in craniofacial surgery.
Craniomaxillofac Trauma Reconstr. 2009;2:125e134.
3. Oppenheimer AJ, Tong L, Buchman SR. Craniofacial bone
grafting: Wolff’s law revisited. Craniomaxillofac Trauma
Reconstr. 2008;1:49e61.
4. Turan A, Kostakoglu N, Tuncel U, Gokce E, Markoc F. Scapular
bone grafts: good options for craniofacial defects? Ann Plast
Surg. 2014 [In press].
5. Teven CM, Fisher S, Ameer GA, He TC, Reid RR. Biomimetic
approaches to complex craniofacial defects. Ann Maxillofac
Surg. 2015 [In press].
6. Cho YR, Gosain AK. Biomaterials in craniofacial reconstruction.
Clin Plast Surg. 2004;31:377e385. v.
7. Greenwald JA, Mehrara BJ, Spector JA, et al. Biomolecular
mechanisms of calvarial bone induction: immature versus
mature dura mater. Plast Reconstr Surg. 2000;105:1382e1392.
8. Cei S, Mair B, Kandler B, Gabriele M, Watzek G, Gruber R. Age-
related changes of cell outgrowth from rat calvarial and
mandibular bone in vitro. J Craniomaxillofac Surg. 2006;34:
387e394.
9. Hurvitz KA, Kobayashi M, Evans GR. Current options in head and
neck reconstruction. Plast Reconstr Surg. 2006;118:122ee133e.
10. Gosain AK, Persing JA. Biomaterials in the face: benefits and
risks. J Craniofac Surg. 1999;10:404e414.11. Acarturk TO, Hollinger JO. Commercially available demineral-
ized bone matrix compositions to regenerate calvarial critical-
sized bone defects. Plast Reconstr Surg. 2006;118:862e873.
12. Chenard KE, Teven CM, He TC, Reid RR. Bone morphogenetic
proteins in craniofacial surgery: current techniques, clinical
experiences, and the future of personalized stem cell therapy.
J Biomed Biotechnol. 2012;2012:601549.
13. Teven CM, Greives M, Natale RB, et al. Differentiation of
osteoprogenitor cells is induced by high-frequency pulsed
electromagnetic fields. J Craniofac Surg. 2012;23:586e593.
14. Meijer GJ, de Bruijn JD, Koole R, van Blitterswijk CA. Cell-
based bone tissue engineering. PLoS Med. 2007;4:e9.
15. Neovius E, Engstrand T. Craniofacial reconstruction with bone
and biomaterials: review over the last 11 years. J Plast
Reconstr Aesthet Surg. 2010;63:1615e1623.
16. Chim H, Gosain AK. Biomaterials in craniofacial surgery:
experimental studies and clinical application. J Craniofac
Surg. 2009;20:29e33.
17. Gautschi OP, Frey SP, Zellweger R. Bone morphogenetic pro-
teins in clinical applications. ANZ J Surg. 2007;77:626e631.
18. Shenaq DS, Teven CM, Seitz IA, et al. Characterization of
reversibly immortalized calvarial mesenchymal progenitor
cells. J Craniofacial Surg. 2015;26(4):1207e1213.
19. Smith DM, Afifi AM, Cooper GM, Mooney MP, Marra KG,
Losee JE. BMP-2-based repair of large-scale calvarial defects in
an experimental model: regenerative surgery in cranioplasty. J
Craniofac Surg. 2008;19:1315e1322.
20. Hasegawa Y, Shimada K, Suzuki N, et al. The in vitro osteo-
genetic characteristics of primary osteoblastic cells from a
rabbit calvarium. J Oral Sci. 2008;50:427e434.
21. Cheng H, Jiang W, Phillips FM, et al. Osteogenic activity of the
fourteen types of human bone morphogenetic proteins (BMPs).
J Bone Jt Surg Am. 2003;85-A:1544e1552.
22. Kang Q, Sun MH, Cheng H, et al. Characterization of the
distinct orthotopic bone-forming activity of 14 BMPs using re-
combinant adenovirus-mediated gene delivery. Gene Ther.
2004;11:1312e1320.
23. He TC. Distinct osteogenic activity of BMPs and their ortho-
paedic applications. J Musculoskelet Neuronal Interact. 2005;
5:363e366.
24. Westerman KA, Leboulch P. Reversible immortalization of
mammalian cells mediated by retroviral transfer and site-specific
recombination. Proc Natl Acad Sci U S A. 1996;93:8971e8976.
25. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A
simplified system for generating recombinant adenoviruses.
Proc Natl Acad Sci U S A. 1998;95:2509e2514.
26. Kang Q, Song WX, Luo Q, et al. A comprehensive analysis of the
dual roles of BMPs in regulating adipogenic and osteogenic
differentiation of mesenchymal progenitor cells. Stem Cells
Dev. 2009;18:545e559.
27. Luo J, Deng ZL, Luo X, et al. A protocol for rapid generation of
recombinant adenoviruses using the AdEasy system. Nat Pro-
toc. 2007;2:1236e1247.
28. Wang J, Zhang H, Zhang W, et al. Bone morphogenetic protein-
9 effectively induces osteo/odontoblastic differentiation of
the reversibly immortalized stem cells of dental apical papilla.
Stem Cells Dev. 2014;23:1405e1416.
29. Huang E, Bi Y, Jiang W, et al. Conditionally immortalized
mouse embryonic fibroblasts retain proliferative activity
without compromising multipotent differentiation potential.
PLoS One. 2012;7:e32428.
30. Zhang W, Deng ZL, Chen L, et al. Retinoic acids potentiate
BMP9-induced osteogenic differentiation of mesenchymal
progenitor cells. PLoS One. 2010;5:e11917.
31. Huang E, Zhu G, Jiang W, et al. Growth hormone synergizes
with BMP9 in osteogenic differentiation by activating the
JAK/STAT/IGF1 pathway in murine multilineage cells. J Bone
Min Res. 2012;27:1566e1575.
Osteogenic capacity of BMP-9 27532. Luo J, Tang M, Huang J, et al. TGFbeta/BMP type I receptors
ALK1 and ALK2 are essential for BMP9-induced osteogenic
signaling in mesenchymal stem cells. J Biol Chem. 2010;285:
29588e29598.
33. Chen L, Jiang W, Huang J, et al. Insulin-like growth factor 2
(IGF-2) potentiates BMP-9-induced osteogenic differentiation
and bone formation. J Bone Min Res. 2010;25:2447e2459.
34. Zhang H, Wang J, Deng F, et al. Canonical Wnt signaling acts
synergistically on BMP9-induced osteo/odontoblastic differen-
tiation of stem cells of dental apical papilla (SCAPs). Bio-
materials. 2015;39:145e154.
35. Lee JC, Kleiber GM, Pelletier AT, Reid RR, Gottlieb LJ. Autol-
ogous immediate cranioplasty with vascularized bone in high-
risk composite cranial defects. Plast Reconstr Surg. 2013;132:
967e975.
36. Lee K, Silva EA, Mooney DJ. Growth factor delivery-based tis-
sue engineering: general approaches and a review of recent
developments. J R Soc Interface. 2011;8:153e170.
37. Takahashi Y, Yamamoto M, Yamada K, Kawakami O, Tabata Y.
Skull bone regeneration in nonhuman primates by controlled
release of bone morphogenetic protein-2 from a biodegradable
hydrogel. Tissue Eng. 2007;13:293e300.
38. Shenaq DS, Teven CM, He TC, Reid RR. The osteogenic char-
acteristics of immortalized calvarial cells. Plast Reconstr Surg.
2011;128:624.
39. Shah MM, Smyth MD, Woo AS. Adverse facial edema associated
with off-label use of recombinant human bone morphogeneticprotein-2 in cranial reconstruction for craniosynostosis. Case
report. J Neurosurg Pediatr. 2008;1:255e257.
40. Herford AS, Boyne PJ. Reconstruction of mandibular continuity
defects with bone morphogenetic protein-2 (rhBMP-2). J Oral
Maxillofac Surg. 2008;66:616e624.
41. Luther G, Wagner ER, Zhu G, et al. BMP-9 induced osteogenic
differentiation of mesenchymal stem cells: molecular mecha-
nism and therapeutic potential. Curr Gene Ther. 2011;11:
229e240.
42. Cho JY, Lee WB, Kim HJ, et al. Bone-related gene profiles in
developing calvaria. Gene. 2006;372:71e81.
43. Peng Y, Kang Q, Cheng H, et al. Transcriptional characteriza-
tion of bone morphogenetic proteins (BMPs)-mediated osteo-
genic signaling. J Cell Biochem. 2003;90:1149e1165.
44. Xu Y, Malladi P, Zhou D, Longaker MT. Molecular and cellular
characterization of mouse calvarial osteoblasts derived from
neural crest and paraxial mesoderm. Plast Reconstr Surg. 2007;
120:1783e1795.
45. Bruder SP, Fox BS. Tissue engineering of bone. Cell based
strategies. Clin Orthop Relat Res. 1999;(367 suppl):S68eS83.
46. Sundelacruz S, Kaplan DL. Stem cell- and scaffold-based tissue
engineering approaches to osteochondral regenerative medi-
cine. Semin Cell Dev Biol. 2009;20:646e655.
47. Alden TD, Beres EJ, Laurent JS, et al. The use of bone
morphogenetic protein gene therapy in craniofacial bone
repair. J Craniofac Surg. 2000;11:24e30.
